These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12897104)

  • 1. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency.
    Ota K; Akizawa T; Hirasawa Y; Agishi T; Matsui N
    Nephrol Dial Transplant; 2003 Aug; 18(8):1623-30. PubMed ID: 12897104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
    Matsuo T; Koide M; Kario K
    Artif Organs; 1997 Sep; 21(9):1035-8. PubMed ID: 9288875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.
    Matsuo T; Yamada T; Yamanashi T; Kodama K
    Clin Lab Haematol; 1989; 11(3):213-9. PubMed ID: 2686903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model.
    Sakai M; Ohteki H; Narita Y; Naitoh K; Natsuaki M; Itoh T
    Cardiovasc Surg; 1999 Mar; 7(2):187-94. PubMed ID: 10353669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
    Sun X; Chen Y; Xiao Q; Wang Y; Zhou J; Ma Z; Xiang J; Chen X
    Nephrol Dial Transplant; 2011 Sep; 26(9):2954-9. PubMed ID: 21303963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant therapy in a congenital antithrombin III (ATIII)-deficient patient with chronic renal failure undergoing regular hemodialysis.
    Matsuo T; Yamada T; Matsuo M; Sakai R
    Biomater Artif Cells Immobilization Biotechnol; 1991; 19(1):185-91. PubMed ID: 1751668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodialysis without anticoagulant: haemostasis parameters, fibrinogen kinetic, and dialysis efficiency.
    Româo JE; Fadil MA; Sabbaga E; Marcondes M
    Nephrol Dial Transplant; 1997 Jan; 12(1):106-10. PubMed ID: 9027783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of argatroban as an anticoagulant and antithrombin agent in Japan.
    Ikoma H
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():23-8. PubMed ID: 12811008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of newly developed technology in blood coagulation disorders].
    Matsuo T
    Rinsho Byori; 2002 May; 50(5):506-12. PubMed ID: 12078050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis.
    Treichl B; Bachler M; Lorenz I; Friesenecker B; Oswald E; Schlimp CJ; Pedross F; Fries D
    Semin Thromb Hemost; 2015 Feb; 41(1):61-7. PubMed ID: 25594496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of argatroban as an anticoagulant in burn-related severe acquired antithrombin III deficiency after heparin failure.
    Gorman R; Gordan L; Zumberg M; Kitchens C
    Thromb Haemost; 2001 Dec; 86(6):1596-7. PubMed ID: 11776342
    [No Abstract]   [Full Text] [Related]  

  • 14. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE; White RH
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical issues in the development of argatroban: a perspective.
    Fareed J; Hoppensteadt D; Iqbal O; Tobu M; Lewis BE
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():56-65. PubMed ID: 12811013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of argatroban: experiences in continuous renal replacement therapy in critically ill patients after cardiac surgery.
    Klingele M; Bomberg H; Lerner-Gräber A; Fliser D; Poppleton A; Schäfers HJ; Groesdonk HV
    J Thorac Cardiovasc Surg; 2014 Jun; 147(6):1918-24. PubMed ID: 24485959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodialysis in patients treated with oral anticoagulant: should we heparinize?
    Krummel T; Scheidt E; Borni-Duval C; Bazin D; Lefebvre F; Nguyen P; Hannedouche T
    Nephrol Dial Transplant; 2014 Apr; 29(4):906-13. PubMed ID: 24459138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
    Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
    Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
    Escolar G; Bozzo J; Maragall S
    Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.